Logo
LATAM FABRY DISEASE MARKET ANALYSIS
  2. / Market Insights
  3. LATAM Fabry Disease Market Analysis
We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

LATAM FABRY DISEASE MARKET ANALYSIS

LATAM Fabry Disease Market, by Therapy Type (Enzyme Replacement Therapy (Agalsidase Beta (Fabrazyme), Agalsidase Alfa (Replagal), Pegunigalsidase Alfa (PRX-102, Phase III)) Chaperon Therapy (Migalastat (Galafold Phase III)), Substrate Reduction Therapy (Lucerastat (Phase III), Venglustat (Phase III))), by Route of Administration (Oral, Parenteral), by Distribution Channel (Hospitals Pharmacies, Online pharmacies, Retail Pharmacies), and by Country (Brazil, Argentina, Mexico, Rest of Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

  • Published In : Sep 2022
  • Code : CMI5249
  • Pages :245
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Regional Analysis

  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Press Release

LATAM Fabry Disease Market to Surpass US$ 136.890 Mn by 2030
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.